Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
KPTI's Cash to Debt is ranked higher than
89% of the 1159 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.17 vs. KPTI: No Debt )
KPTI' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.94
KPTI's Equity to Asset is ranked higher than
98% of the 1084 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. KPTI: 0.94 )
KPTI' s 10-Year Equity to Asset Range
Min: -21.26   Max: 0.98
Current: 0.94

-21.26
0.98
Z-Score: 45.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -33266.23
KPTI's Operating margin (%) is ranked lower than
57% of the 1110 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.84 vs. KPTI: -33266.23 )
KPTI' s 10-Year Operating margin (%) Range
Min: -33120.52   Max: -2506.31
Current: -33266.23

-33120.52
-2506.31
Net-margin (%) -33235.53
KPTI's Net-margin (%) is ranked lower than
57% of the 1110 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. KPTI: -33235.53 )
KPTI' s 10-Year Net-margin (%) Range
Min: -33090.39   Max: -2505.99
Current: -33235.53

-33090.39
-2505.99
ROE (%) -43.79
KPTI's ROE (%) is ranked higher than
50% of the 1139 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.62 vs. KPTI: -43.79 )
KPTI' s 10-Year ROE (%) Range
Min: -53.44   Max: -41.9
Current: -43.79

-53.44
-41.9
ROA (%) -42.07
KPTI's ROA (%) is ranked lower than
52% of the 1170 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.52 vs. KPTI: -42.07 )
KPTI' s 10-Year ROA (%) Range
Min: -372.3   Max: -40.03
Current: -42.07

-372.3
-40.03
ROC (Joel Greenblatt) (%) -5699.35
KPTI's ROC (Joel Greenblatt) (%) is ranked lower than
55% of the 1165 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.08 vs. KPTI: -5699.35 )
KPTI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -11975.31   Max: -5066.53
Current: -5699.35

-11975.31
-5066.53
» KPTI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

KPTI Guru Trades in Q1 2014

Steven Cohen Sold Out
» More
Q2 2014

KPTI Guru Trades in Q2 2014

Paul Tudor Jones 15,000 sh (New)
Steven Cohen 8,000 sh (unchged)
» More
Q3 2014

KPTI Guru Trades in Q3 2014

Steven Cohen 39,400 sh (+392.50%)
Paul Tudor Jones Sold Out
» More
Q4 2014

KPTI Guru Trades in Q4 2014

Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with KPTI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Karyopharm Therapeutics Inc.

Weekly CEO Sells Highlight: Karopharm Therapeuticcs Inc., Methode Electronics Inc., Gilead Sciences Inc. and Nimble Storage Inc.
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: Karopharm Therapeuticcs Inc, Methode Electronics Inc, Gilead Sciences Inc, and Nimble Storage Inc. Read more...

Ratios

vs
industry
vs
history
P/B 5.40
KPTI's P/B is ranked higher than
62% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.24 vs. KPTI: 5.40 )
KPTI' s 10-Year P/B Range
Min: 3.25   Max: 10.64
Current: 5.4

3.25
10.64
P/S 3945.67
KPTI's P/S is ranked lower than
75% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.24 vs. KPTI: 3945.67 )
KPTI' s 10-Year P/S Range
Min: 105.69   Max: 4712
Current: 3945.67

105.69
4712
Current Ratio 16.89
KPTI's Current Ratio is ranked higher than
97% of the 1155 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. KPTI: 16.89 )
KPTI' s 10-Year Current Ratio Range
Min: 0.49   Max: 47.98
Current: 16.89

0.49
47.98
Quick Ratio 16.89
KPTI's Quick Ratio is ranked higher than
98% of the 1155 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. KPTI: 16.89 )
KPTI' s 10-Year Quick Ratio Range
Min: 0.49   Max: 47.98
Current: 16.89

0.49
47.98

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.90
KPTI's Price/Net Cash is ranked higher than
96% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. KPTI: 4.90 )
KPTI' s 10-Year Price/Net Cash Range
Min: 4.47   Max: 6.37
Current: 4.9

4.47
6.37
Price/Net Current Asset Value 4.90
KPTI's Price/Net Current Asset Value is ranked higher than
94% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. KPTI: 4.90 )
KPTI' s 10-Year Price/Net Current Asset Value Range
Min: 4.41   Max: 6.3
Current: 4.9

4.41
6.3
Price/Tangible Book 4.60
KPTI's Price/Tangible Book is ranked higher than
73% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. KPTI: 4.60 )
KPTI' s 10-Year Price/Tangible Book Range
Min: 4.4   Max: 10.51
Current: 4.6

4.4
10.51
Price/Median PS Value 1.00
KPTI's Price/Median PS Value is ranked higher than
90% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. KPTI: 1.00 )
KPTI' s 10-Year Price/Median PS Value Range
Min: 0.13   Max: 1.27
Current: 1

0.13
1.27
Earnings Yield (Greenblatt) -8.70
KPTI's Earnings Yield (Greenblatt) is ranked lower than
55% of the 1155 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. KPTI: -8.70 )
KPTI' s 10-Year Earnings Yield (Greenblatt) Range
Min: -10.9   Max: 0
Current: -8.7

-10.9
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:25K.Germany,
» More Articles for KPTI

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Karopharm Therapeuticcs Inc., Methode Electronics Inc., Gilead Sciences Jul 06 2014 

More From Other Websites
Nasdaq stocks posting largest percentage decreases Apr 29 2015
Karyopharm to Present Late-Breaking Data at American Association for Cancer Research Annual Meeting Apr 17 2015
Karyopharm to Present Late-Breaking Data at American Association for Cancer Research Annual Meeting Apr 17 2015
Karyopharm Granted U.S. Composition-of-Matter Patent for Selinexor (KPT-330) Apr 13 2015
Karyopharm Granted U.S. Composition-of-Matter Patent for Selinexor (KPT-330) Apr 13 2015
Lightning Round: Be careful-this lurks everywhere Apr 01 2015
Karyopharm Appoints Mikael Dolsten, MD, PhD to Its Board of Directors Apr 01 2015
KARYOPHARM THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers Apr 01 2015
Karyopharm Appoints Mikael Dolsten, MD, PhD to Its Board of Directors Apr 01 2015
Nature Neuroscience Publishes Data Demonstrating Potential Therapeutic Benefits of Karyopharm's... Mar 24 2015
Karyopharm to Report Fourth Quarter and Full Year 2014 Financial Results on March 16, 2015 Mar 24 2015
Karyopharm Reports Fourth Quarter and Full Year 2014 Financial Results and Highlights Recent... Mar 24 2015
Karyopharm to Present Data on Oncology Pipeline at American Association for Cancer Research Annual... Mar 24 2015
Karyopharm to Present Data on Its Novel Oral PAK4 Allosteric Modulator (PAM) at the American... Mar 24 2015
5 Biotech Stocks On JMP's Radar Mar 20 2015
KARYOPHARM THERAPEUTICS INC. Financials Mar 20 2015
Karyopharm to Present Data on Its Novel Oral PAK4 Allosteric Modulator (PAM) at the American... Mar 18 2015
Karyopharm to Present Data on Oncology Pipeline at American Association for Cancer Research Annual... Mar 18 2015
Karyopharm Therapeutics Inc Earnings Call scheduled for 8:30 am ET today Mar 16 2015
KARYOPHARM THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK